Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)

Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910) - Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003737

Enrollment

Registered

2010-06-11

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-squamous non-small cell lung cancer with EGFR Mutation

Interventions

Patients receive Pemetrexed 500mg/m2 day1 + Carboplatin AUC6 day1 + Bevacizumab 15mg/kg day1, q3w, 4-6 cycles. Patients who achieved disease control receive Pemetrexed 500mg/m2 day1 + Bevacizumab 15

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven non-squamous non small cell lung cancer 2) Patients with EGFR mutation (exon 19 deletion or L858R) 3) Patients with stage IIIB or IV, or recurrent disease after surgery and was not a candidate for curative radiotherapy 4) No prior chemotherapy 5) Patient who has measurable lesion by RECIST 6) Age: 20-74 7) ECOG PS: 0-1 8) Adequate organ function 9) Life expectancy more than 3 months 10) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Brain metastasis 2) Hemoptysis (>=2.5ml) 3) Active infection 4) Fever 5) Serious disease condition 6) Active double cancer 7) Cavity fluid retention difficult to control 8) Severe drug allergy 9) Receiving anticoagulant drug (except Aspirin under 325mg/day) 10) Active GI bleeding or inflammation in the abdominal cavity. 11) Pregnancy or lactation 12) Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Safety Disease control rate Overall survival Progression free survival	—

Countries

Japan

Contacts

Public ContactTomoki Kimura

Tosei General Hospital Respiratory medicine and allergy

lung@tosei.or.jp0561-82-5101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026